Contrast induced nephropathy (CIN) is the third leading cause of hospital aquired renal failure and is associated with significant morbidity and mortality. Chronic kidney disease is the primary predisposing factor for CIN. As estimated glomerular filtration rate <60 ml/1.73 m 2 represents significant renal dysfunction and defines patients at high risk. Modifiable risk factors for CIN include hydration status, the type and amount of contrast, use of concomitant nephrotoxic agents and recent contrast administration. The cornerstone of CIN prevention, in both the high and low risk patients, is adequate parenteral volume repletion. In the patient at increased risk for CIN it is often appropriate to withhold potentially nephrotoxic medications, and consider the use of n-acetylcysteine. In patients at increased risk for CIN the use of low or iso-osomolar contrast agents should be utilized and strategies employed to minimize contrast volume. In these patients serum creatinine should be obtained forty-eight hours post procedure and it is often appropriate to continue withholding medications such as metformin or non steroidal anti-inflammatories until renal function returns to normal.' 2006 Wiley-Liss, Inc.

This preliminary results suggest that this easy technical method may be useful in the treatment of life-threatening pulmonary embolism in patients with absolute contraindications to thrombolytic therapy. A larger cohort of patients is necessary to determine whether this treatment should be proposed as an alternative to the use of fibrinolytics in selected patients.

Percutaneous closure of a secundum atrial septal defect was performed successfully via the jugular approach in a 77-year-old patient with heparin-induced thrombocytopenia and total occlusion of the inferior vena cava using the Amplatzer septal occluder after an unsuccessful attempt using the CardioSEAL septal occluder. This case demonstrates the advantages of the jugular approach in the patient with difficult anatomy and the advantage of the Amplatzer over the CardioSEAL device in this situation.

To date, one third of patients with symptomatic aortic stenosis are not operated on because of advanced age, depressed left ventricular function, or comorbidities. Whereas balloon aortic valvuloplasty can be used as a palliative treatment in this population, the hemodynamic and clinical benefits of the procedure are only temporary. With the goal of offering to this subset of patients a nonsurgical therapeutic option with improved results and longer term positive outcomes, we developed a percutaneous implantable bioprosthetic heart valve able to be inserted within the native diseased aortic valve using cardiac catheterization techniques. The first human implant was performed by our group in April 2002 using the antegrade transeptal approach. Since then, we have implanted the valve on compassionate basis in a series of nonsurgical elderly patients with end‐stage aortic stenosis and multiple comorbidities, all declined by cardiac surgeons for valve replacement. This article describes the technical improvements of the device and implantation protocols, provides clinical results of the first series of patients, and outlines strategies for future development of the percutaneous heart valve.